Who is sponsoring NCT02971176?

NCT02971176 is sponsored by Xuzhou Central Hospital.

What drugs are being tested in NCT02971176?

Interventions in NCT02971176: Low-dose protocol computed tomography, Standard-dose protocol computed tomography.

What condition does NCT02971176 study?

NCT02971176 studies Lung Cancer, Adenocarcinoma, Lung Inflammatory Pseudotumor.

Is NCT02971176 still recruiting?

NCT02971176 is currently completed. Last updated 4 June 2019.

Last reviewed 2019-06-04 · How we verify

NCT02971176

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Protocol for Computed Tomography-guided Lung Biopsy

Completed NA Last updated 4 June 2019

What this trial tests

NA trial testing Low-dose protocol computed tomography in Lung Cancer, Adenocarcinoma in 280 participants. Completed in 31 May 2019.

Timeline

30 November 2016

Primary endpoint
31 May 2019

31 May 2019

Quick facts

Lead sponsor	Xuzhou Central Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	280
Start date	30 November 2016
Primary completion	31 May 2019
Estimated completion	31 May 2019
Sites	1 location across China

Drugs / interventions tested

Low-dose protocol computed tomography
Standard-dose protocol computed tomography

Conditions studied

Lung Cancer, Adenocarcinoma — all drugs for Lung Cancer, Adenocarcinoma →
Lung Inflammatory Pseudotumor — all drugs for Lung Inflammatory Pseudotumor →

Sponsor

Xuzhou Central Hospital

Who can join

Adults 18 to 90, any sex, with Lung Cancer, Adenocarcinoma or Lung Inflammatory Pseudotumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the diagnostic accuracy and complication rate between low-dose computed tomography-guided and standard-dose computed tomography-guided lung biopsy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Computed tomography-guided lung biopsy: a randomized controlled trial of low-dose versus standard-dose protocol.
Fu YF, Li GC, Xu QS, Shi YB, et al · · 2020 · cited 32× · PMID 31776740 · DOI 10.1007/s00330-019-06464-6

Verify or expand the search:

Other Xuzhou Central Hospital trials

Trials by the same sponsor.

NCT06126289 — CSF Single-cell Sequencing and Proteomics of Chronic Postsurgical Pain in Patients With Lower Limb Fractures · unknown
NCT06136663 — Prevalence and Risk Factors for Postsurgical Pain After the Open Reduction and Internal Fixation of Lower Limbs. · unknown
NCT06050096 — DCB Treatment in CTO Guided by IVUS · unknown
NCT06395961 — Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot · NA · enrolling by invitation
NCT05772026 — Plasma Proteomics in Patients With Postoperative Delirium · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02971176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuzhou Central Hospital
Last refreshed: 4 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02971176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing